Patents Issued in April 18, 2024
  • MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS
    Publication number: 20240123035
    Abstract: The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity.
    Type: Application
    Filed: March 2, 2023
    Publication date: April 18, 2024
    Inventors: Antonin DE FOUGEROLLES, Kristy M. Wood, Sayda M. ELBASHIR, Noubar B. Afeyan, Pedro VALENCIA, Jason P. SCHRUM
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF GRAFT VERSUS HOST DISEASE
    Publication number: 20240123036
    Abstract: This application is directed to methods of treating Graft versus Host Disease (GvHD), specifically acute GvHD and acute gastrointestinal GvHD, using apraglutide.
    Type: Application
    Filed: January 28, 2022
    Publication date: April 18, 2024
    Inventors: Violetta DIMITRIADOU, Nader N. YOUSSEF
  • GLUCAGON ANALOGUES AS LONG-ACTING GLP-1/GLUCAGON RECEPTOR AGONISTS IN THE TREATMENT OF FATTY LIVER DISEASE AND STEATOHEPATITIS
    Publication number: 20240123037
    Abstract: The present invention relates to the medical use of specific long-acting glucagon analogues having dual GLP-1/glucagon receptor agonist activity in the prevention and/or treatment of metabolic liver disease, particularly non-alcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), NAFLD-associated liver fibrosis and/or cirrhosis.
    Type: Application
    Filed: September 28, 2023
    Publication date: April 18, 2024
    Inventor: Leo THOMAS
  • PTH Prodrugs
    Publication number: 20240123038
    Abstract: The present invention relates to PTH prodrugs, pharmaceutical compositions comprising such PTH prodrugs and their uses.
    Type: Application
    Filed: September 8, 2023
    Publication date: April 18, 2024
    Inventors: Kennett Sprogøe, Felix Cleemann, Guillaume Maitro, Mathias Krusch, Thomas Wegge, Joachim Zettler
  • DETOXIFICATION PREPARATIONS WITH REINFORCED BOOSTERS TO TREAT ALCOHOL INTOXICATION
    Publication number: 20240123039
    Abstract: A composition and method for converting alcohol to acetaldehyde and/or acetate and treat alcohol intoxication. The composition can include a therapeutically effective amount of an enzyme and a therapeutically effective amount of a co-factor. The enzymes can be alcohol dehydrogenase (ADH), a derivative of alcohol dehydrogenase, an analog of alcohol dehydrogenase or alcohol dehydrogenase in yeast crude extract. A second enzyme can be aldehyde dehydrogenase (ALDH), a derivative of aldehyde dehydrogenase, an analog of aldehyde dehydrogenase, mitochondrial aldehyde dehydrogenase (ALDH2), a derivative of mitochondrial aldehyde dehydrogenase, an analog of mitochondrial aldehyde dehydrogenase or aldehyde dehydrogenase in yeast crude extract. A co-factor can be utilized in the composition that increases a concentration of Nicotinamide Adenine Dinucleotide (NAD) or Nicotinamide Adenine Dinucleotide Phosphate (NADP).
    Type: Application
    Filed: October 12, 2023
    Publication date: April 18, 2024
    Inventor: Richard C.K. Yen
  • COMPOSITIONS, DEVICES AND METHODS FOR TREATING MPS VI DISEASE
    Publication number: 20240123040
    Abstract: Described herein are mammalian cells engineered to express and secrete an ARSB protein and optionally a sialytransferase protein, as well as compositions, implantable devices and device preparations comprising the engineered cells, and methods of making and using the same for treating MPS VI disease.
    Type: Application
    Filed: February 4, 2022
    Publication date: April 18, 2024
    Inventors: Elina Makino, Erika Pearson
  • Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration
    Publication number: 20240123041
    Abstract: The present disclosure discloses compositions comprising a hyaluronidase, devices comprising such compositions, as well as methods and uses employing such compositions and devices to reduce or eliminate a hyaluronic acid-induced blockage of one or more blood vessels supplying an eye of an individual; methods and uses for employing such compositions and devices to reduce or inhibit a vascular occlusion in an eye of an individual; and methods and uses for employing such compositions and devices to reduce or inhibit a hyaluronic acid-induced loss of vision of an individual.
    Type: Application
    Filed: December 21, 2023
    Publication date: April 18, 2024
    Applicant: Med Progress, LLC
    Inventor: Steve Yoelin
  • METHODS AND COMPOSITIONS RELATED TO A TISSUE FACTOR-TARGETING IGG3 IMMUNOCONJUGATES
    Publication number: 20240123042
    Abstract: Disclosed are methods and compositions related to immunoconjugates. Particularly disclosed are immunoconjugates that comprise the Fc portion of IgG3 as well as Factor VII light chain or Factor VII. Also disclosed is an immunoconjugate protein, wherein said immunoconjugate protein comprises a hybrid Fc region of an IgG1 and an IgG3 immunoglobulin conjugated to Factor VII. These immunoconjugates can target Tissue Factor (TF) expressing cells.
    Type: Application
    Filed: December 5, 2023
    Publication date: April 18, 2024
    Inventor: Zhiwei HU
  • PHARMACEUTICAL COMPOSITIONS COMPRISING RANPIRNASE
    Publication number: 20240123043
    Abstract: This disclosure is directed to new pharmaceutical compositions comprising ranpimase and a polyol, said compositions comprise increased stability. Further disclosed are methods for treating a viral disease by administering said compositions.
    Type: Application
    Filed: February 21, 2022
    Publication date: April 18, 2024
    Applicant: Orgenesis Inc.
    Inventor: Keith Arthur JOHNSON
  • PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST NON-SMALL CELL LUNG CANCER AND OTHER CANCERS
    Publication number: 20240123044
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: October 19, 2023
    Publication date: April 18, 2024
    Inventors: Toni WEINSCHENK, Oliver SCHOOR, Andrea MAHR
  • NONAUTOLOGOUS MULTI-STRESSED CANCER CELLS AND USES THEREOF FOR VACCINATING AND TREATING CANCERS
    Publication number: 20240123045
    Abstract: Advanced therapy medicinal products (AMTPs) for cell therapy. In particular, a composition including stressed HT-29, HCT-116 and LoVo cells, and immunogenic stress proteins produced by these cells in response to stresses applied in vitro. The composition allows to simultaneously counteract multiple cell resistance mechanisms observed in situ in cancer cells, and is therefore suitable for vaccinating and treating cancers in human patients.
    Type: Application
    Filed: February 25, 2022
    Publication date: April 18, 2024
    Applicant: BRENUS PHARMA
    Inventors: Benoit PINTEUR, Paul BRAVETTI
  • IMMUNOGENIC COMPOSITIONS
    Publication number: 20240123046
    Abstract: Provided herein are compositions comprising novel MHC class II T cell epitopes and method using thereof. In some embodiments, a composition described herein comprises an immunogenic polypeptide comprising an MHC class II T cell epitope and a target antigen. In some embodiments, the target antigen is a viral, bacterial, parasite or tumor specific antigen. In some embodiments, the target antigen comprises a virus, bacteria, parasite or tumor specific polypeptide. In some embodiments, the composition comprises a fusion polypeptide comprising the immunogenic polypeptide and the target polypeptide. Also provided are polynucleotides encoding the fusion polypeptide, and methods of administering a composition comprising the polynucleotide to a subject to elicit an immune response. In some embodiments, the polynucleotide is an RNA comprising modified ribonucleotides.
    Type: Application
    Filed: December 17, 2021
    Publication date: April 18, 2024
    Inventors: William R. SCHIEF, Kristen COHEN, Julie MCELRATH
  • LIPID NANOPARTICLE ADJUVANT COMPOSITION FOR PNEUMOCOCCAL CONJUGATE VACCINES
    Publication number: 20240123047
    Abstract: The present invention relates generally to the prevention of pneumococcal disease. More specifically, the invention relates to compositions comprising pneumococcal conjugates and a lipid nanoparticle (LNP).
    Type: Application
    Filed: February 2, 2022
    Publication date: April 18, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Julie M. Skinner, William J. Smith
  • ATTENUATED AFRICAN SWINE FEVER VIRUS AND ITS USE AS A VACCINE
    Publication number: 20240123048
    Abstract: The present invention relates to an attenuated African Swine Fever (ASF) virus, wherein: ?genes MGF 360-12L, 360-13L, 360-14L, 505-2R, 505-3R are deleted or are interrupted or mutated such that the genes are not transcribed and/or translated, ? ORF of ASFV_G_ACD_00520 is deleted or is interrupted or mutated such that it is not transcribed and/or translated, and ? genes MGF 505-1 R et 505-4R are truncated, compared to the genome of the corresponding unattenuated virus. The present invention also refers to a vaccine comprising the attenuated ASF virus, and its use in preventing African Swine Fever in a subject.
    Type: Application
    Filed: January 31, 2022
    Publication date: April 18, 2024
    Inventors: Marie-Frédérique BLOT LE POTIER, Olivier BOURRY, Evelyne HUTET, Mireille LE DIMNA, Amélie CHASTAGNER, Frédéric PABOEUF, Yannick BLANCHARD, Pierrick LUCAS
  • CIS-REPLICON CONSTRUCT
    Publication number: 20240123049
    Abstract: Provided is a new-type cis-replicon construct for efficiently expressing a target protein, which comprises an RNA polymerase coding unit and a target protein coding unit. The replicon construct can drive the replication of the target protein coding unit and reduce or avoid the replication and expression of the RNA polymerase, thereby effectively improving the expression of the target protein and reducing the expression of the non-target protein.
    Type: Application
    Filed: February 7, 2022
    Publication date: April 18, 2024
    Applicant: ZHENGZHOU UNIVERSITY
    Inventors: Shoutao ZHANG, Qiang MA, Qingnan TIAN, Tian WANG, Yonghui HUANG, Guotao LIU, Zhen TIAN
  • Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C virus
    Publication number: 20240123050
    Abstract: The present invention relates to compositions and methods for inducing an adaptive immune response against Hepatitis C virus (HCV) in a subject. In some embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof. For example, in some embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof.
    Type: Application
    Filed: May 1, 2023
    Publication date: April 18, 2024
    Inventors: Drew Weissman, George M. Shaw, Justin R. Bailey, Stuart C. Ray, James Crowe, Jr., Andrew Flyak
  • ZIKA VIRUS VACCINE
    Publication number: 20240123051
    Abstract: The present disclosure relates to vaccines and methods for the prevention and treatment of Zika virus infection. Particularly, the present disclosure relates to viral and DNA vaccine vectors which includes or encode for secreted immunogenic peptides of NS1 that eliciting a protective immune response and prevent Zika virus infection of a subject.
    Type: Application
    Filed: June 13, 2023
    Publication date: April 18, 2024
    Applicant: THE UNIVERSITY OF ADELAIDE
    Inventors: Eric James Gowans, Branka Grubor-Bauk, Danushka Wijesundara
  • Vaccines For Recurrent Respiratory Papillomatosis And Methods of Using the Same
    Publication number: 20240123052
    Abstract: Provided herein are nucleic acid molecules encoding an HPV antigen. Also provided are vaccines against human papillomavirus (HPV) comprising the nucleic acids, methods of inducing immune responses, and methods for prophylactically and/or therapeutically immunizing individuals against recurrent respiratory papillomatosis (RRP). Pharmaceutical compositions, recombinant vaccines comprising DNA plasmid and live attenuated vaccines are disclosed as well as methods of inducing an immune response to treat or prevent RRP are disclosed.
    Type: Application
    Filed: October 13, 2023
    Publication date: April 18, 2024
    Inventors: Stephanie Ramos, Jewell Walters, Jian Yan, Anna Slager, Charles Reed, Kate Broderick
  • CORONAVIRUS VACCINE THROUGH NASAL IMMUNIZATION
    Publication number: 20240123053
    Abstract: The invention generally discloses coronavirus vaccine for coronavirus disease. Particularly, the invention discloses coronavirus vaccine through nasal immunization. More particularly, the invention describes and develop a preventive vaccine against infection or disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) through nasal immunization in mammals. Specifically, the invention describes human adenovirus which is engineered to express SARS-CoV-2 spike protein or part/fragment thereof which elicit immune response against the SARS-CoV-2 in mammals, and it is also suitable for immunizing human subjects. Describes the method of production of novel adenovirus vectors, use thereof in vaccine composition, vaccine formulation, preparation, and method of treatment of COVID-19 using above said novel vectors and compositions thereof.
    Type: Application
    Filed: May 7, 2021
    Publication date: April 18, 2024
    Applicant: BHARAT BIOTECH INTERNATIONAL LIMITED
    Inventors: Krishna Murthy ELLA, Krishna Mohan VADREVU, Raches ELLA, Raju SUNAGAR
  • CORONAVIRUS ANTIGENS AND EPITOPES AND PROTEINS THAT BIND THERETO
    Publication number: 20240123054
    Abstract: Provided are highly conserved antigens and epitopes of SARS-CoV-2 that can be used in vaccines and to produce bindings proteins (e.g.
    Type: Application
    Filed: February 18, 2022
    Publication date: April 18, 2024
    Inventors: Joseph COTROPIA, Gaurav Chandra
  • Vaccines and Antibodies for the Treatment and Prevention of Microbial Infections
    Publication number: 20240123055
    Abstract: The invention relates to compositions and peptides or peptide sequences that induce an immune response in an animal or a mammal that is protective against infection by one or more pathogens. In addition, the invention relates to immunogenic composition and vaccines comprising compositions and peptide sequences and to method for treating and preventing an infection in animals and mammals such as humans and antibodies.
    Type: Application
    Filed: October 16, 2023
    Publication date: April 18, 2024
    Applicant: Longhorn VAccines and Diagnostics, LLC
    Inventors: Gerald W. Fischer, Clara J. Sei, Jeffrey D. Fischer
  • MERS-CoV Vaccine
    Publication number: 20240123056
    Abstract: Disclosed herein is a vaccine comprising a Middle East Respiratory Syndrome coronavirus (MERS-CoV) antigen. The antigen can be a consensus antigen. The consensus antigen can be a consensus spike antigen. Also disclosed herein is a method of treating a subject in need thereof, by administering the vaccine to the subject.
    Type: Application
    Filed: September 28, 2023
    Publication date: April 18, 2024
    Inventors: David Weiner, Karuppiah Muthumani, Niranjan Y. Sardesai
  • Recombinant Non-Pathogenic Marek's Disease Virus Constructs Encoding Infectious Laryngotracheitis Virus and Infectious Bursal Disease Virus Antigens
    Publication number: 20240123057
    Abstract: The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus protein antigens and an Infectious Bursal Disease virus protein antigen, and methods of their use in poultry vaccines.
    Type: Application
    Filed: February 1, 2023
    Publication date: April 18, 2024
    Applicant: Intervet Inc.
    Inventors: Stephanie Cook, Mohamad Morsey, Ian Tarpey, Iwan Verstegen, Paulus Jacobus Antonius Sondermeijer, Paul Vermeij
  • EPITOPE PEPTIDE AND ANTIBODY FOR PREVENTING AND TREATING EB VIRUS INFECTION AND RELATED DISEASES
    Publication number: 20240123058
    Abstract: Provided are an epitope peptide (or a variant thereof) that can be used for preventing or treating an EBV infection, a recombinant protein containing the epitope peptide (or variant thereof) and a carrier protein, and the use of the epitope peptide (or variant thereof) and the recombinant protein. Further provided are an antibody against the epitope peptide, and the use thereof in the detection, prevention and/or treatment of an EBV infection and/or diseases caused by the infection.
    Type: Application
    Filed: January 29, 2022
    Publication date: April 18, 2024
    Inventors: Yixin CHEN, Xiao ZHANG, Junping HONG, Miao XU, Qian WU, Ling ZHONG, Ningshao XIA
  • Kaposi's Sarcoma Associated Herpesvirus Vaccine and Methods of Making and Using Thereof
    Publication number: 20240123059
    Abstract: Disclosed herein are compositions and methods for inducing and/or enhancing complement-mediated neutralization of a herpesvirus.
    Type: Application
    Filed: October 16, 2023
    Publication date: April 18, 2024
    Inventors: Ting-Ting Wu, Alex Lam, Caius Radu
  • IMPROVED THERAPEUTIC COMPOSITION COMPRISING HEPATITIS B ANTIGEN HAVING S, PRE-S1 AND PRE-S2 PROTEIN, ALUMINIUM PHOSPHATE AND INTERFERON-ALPHA AND USE THEREOF FOR TREATMENT OF HEPATITIS B
    Publication number: 20240123060
    Abstract: The present disclosure provides compositions and methods useful for inducing an immune response and overcoming immune tolerance in a subject suffering from Hepatitis B. As described herein, the compositions of the disclosure comprise HBsAg having S, Pre-S1 and Pre-S2 proteins, an aluminum phosphate adjuvant and interferon-?.
    Type: Application
    Filed: June 19, 2020
    Publication date: April 18, 2024
    Inventors: David Evander Anderson, Zhi Hong, Qing Zhu
  • Therapeutic Vaccine for Hepatitis B Virus (HBV) using the HBV Core Antigen
    Publication number: 20240123061
    Abstract: Provided herein are compositions of CD1280 binding proteins and a Hepatitis B virus core antigen (HBcAg) and/or a Hepatitis B virus E antigen (HBeAg), or antigenic fragments or mutants thereof, attached to the CD180 binding protein, and methods for using the compositions to treat or limit the development of hepatitis-B virus (HBV)-related disorders.
    Type: Application
    Filed: December 8, 2023
    Publication date: April 18, 2024
    Inventors: Edward A. CLARK, Deborah L. FULLER, Che-Leung LAW, Amanda MAK
  • BIVALENT DENGUE/HEPATITUS B VACCINES
    Publication number: 20240123062
    Abstract: The present invention relates to the construction of and immunization with viral vaccines. In particular, bivalent vaccines that are capable of providing simultaneous virus infection protection for two or more different viruses. Furthermore, the bivalent vaccines contemplated herein are contemplated as being effective in a neonatal mammal. One such bivalent viral vaccine comprises two antigenic epitopes against the dengue viruses and at least one antigenic epitope against hepatitis B virus. Immunization cross-reactivity may also provide infection protection against other viruses as well.
    Type: Application
    Filed: September 21, 2023
    Publication date: April 18, 2024
    Inventor: Daniel H. Libraty
  • SOYBEAN ALLERGY ANTIGEN
    Publication number: 20240123063
    Abstract: The present invention provides novel antigens of an allergy to soybean, methods and kits for diagnosing an allergy to soybean, pharmaceutical compositions comprising such an antigen, soybeans or processed products of soybean in which such an antigen is eliminated, and a tester for determining the presence or absence of a soybean antigen in an object of interest.
    Type: Application
    Filed: September 7, 2023
    Publication date: April 18, 2024
    Applicant: HOYU CO., LTD.
    Inventors: Kayoko Matsunaga, Akiko Yagami, Naoshi Shimojo, Masashi Nakamura, Nayu Sato
  • CUSTOM AUTOLOGOUS VACCINE COMPOSITION, AND A METHOD FOR ITS MANUFACTURE
    Publication number: 20240123064
    Abstract: An immunogenic composition forming a vaccine includes an autologous cell medium, wherein producing the autologous cell medium further comprises producing the autologous cell medium using at least a call collected from a subject, therein the cell medium includes immune system stem cells, combining an oligonucleotide-based adjuvant with the autologous cell medium and combining an antigen with the autologous cell medium and the oligonucleotide-based adjuvant.
    Type: Application
    Filed: October 13, 2022
    Publication date: April 18, 2024
    Inventor: Joseph CHALIFOUX
  • PHARMACEUTICAL COMPOSITIONS
    Publication number: 20240123065
    Abstract: The present invention relates to pharmaceutical compositions comprising from an antibody or a fragment thereof which binds IL-17A and IL-17F and a combination of glycine, acetate buffer at pH 4.6 to 5.5 and polysorbate 80.
    Type: Application
    Filed: December 22, 2023
    Publication date: April 18, 2024
    Inventors: Sandrine Durran, Andrew Jeffrey Yates
  • COMPOSITION AND METHODS FOR STABILIZING LIQUID PROTEIN FORMULATIONS
    Publication number: 20240123066
    Abstract: The present disclosure provides liquid formulations comprising polypeptides and surfactants. In particular, it discloses a liquid formulation comprising a polypeptide and a surfactant, wherein at least about 70% (wt %) of the surfactant are isosorbide polyoxyethylene (POE) fatty acid esters. The invention also provides methods for making such liquid formulations, articles of manufacture comprising such liquid formulations and methods of treating a patient with such liquid formulations.
    Type: Application
    Filed: December 6, 2023
    Publication date: April 18, 2024
    Applicant: Genentech, Inc.
    Inventors: Anthony TOMLINSON, Barthelemy Luc DEMEULE, Isidro Angelo Eleazar ZARRAGA
  • TREATMENT OF CANCERS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES
    Publication number: 20240123067
    Abstract: Provided herein are methods for generating TILs that can then be employed in the treatment of patients having a cancer (e.g., a pediatric cancer, a uveal melanoma or mesothelioma).
    Type: Application
    Filed: December 16, 2021
    Publication date: April 18, 2024
    Inventors: Friedrich Graf Finck FINCKENSTEIN, Maria FARDIS
  • CD19 BINDERS, CAR-T CONSTRUCTS COMPRISING THE SAME, AND METHODS OF USING THE SAME
    Publication number: 20240123068
    Abstract: The disclosure relates to chimeric antigen receptor (CAR) specific to CD19, vectors encoding the same, and recombinant T cells comprising the CD19 CAR. The disclosure also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD19 binding domain.
    Type: Application
    Filed: October 18, 2023
    Publication date: April 18, 2024
    Applicants: Kite Pharma, Inc., The Trustees of the University of Pennsylvania
    Inventors: Neil C. Sheppard, Yanping Luo, David Barrett, Regina Young
  • ANTIGEN RECOGNIZING RECEPTORS TARGETING UPAR AND USES THEREOF
    Publication number: 20240123069
    Abstract: The presently disclosed subject matter provides for antigen-recognizing receptors that specifically target uPAR and cells comprising such uPAR-targeted antigen-recognizing receptors. The presently disclosed subject matter further provides uses of the uPAR-targeted antigen-recognizing receptors for treatment.
    Type: Application
    Filed: December 11, 2023
    Publication date: April 18, 2024
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES
    Inventors: Scott W. Lowe, Michel Sadelain, Corina Amor Vegas, Zeda Zhang
  • EPITOPE PEPTIDE OF RAS G13D MUTANT AND T CELL RECEPTOR RECOGNIZING RAS G13D MUTANT
    Publication number: 20240123070
    Abstract: The present invention provides an epitope peptide of a RAS G13D mutant, an antigen presenting cell expressing the epitope peptide, a tumor vaccine containing the antigen presenting cell, and a use of the tumor vaccine in the prevention or treatment of a tumor having RAS G13D mutation. The present invention also provides a T cell receptor (TCR) specifically recognizing a RAS G13D mutant, a conjugate and a fusion protein containing the TCR, an immune cell expressing the TCR, a T cell drug containing the immune cell, and a use of the T cell drug in the prevention or treatment of a tumor having RAS G13D mutation.
    Type: Application
    Filed: January 29, 2022
    Publication date: April 18, 2024
    Inventors: Nan Mou, Yue Yu, Jijun Yuan
  • PREPARATION METHOD AND APPLICATION OF CTL CELL
    Publication number: 20240123071
    Abstract: Provided are a preparation method for a CTL cell and an application thereof. The preparation method comprises the following steps of: inducing a CTL cell by using a tumor antigen PAP-GM-CSF sensitized DC cell; and knocking out a PD-1 gene of the CTL cell to obtain a PD-1 knock-out CTL cell. The CTL cell obtained by the preparation method can be used for preparing drugs for treatment of prostate cancer, especially for treating PAP-positive prostate cancer. The CTL cell does not cause CTL cell failure and anergy due to the tumor-expressed PD-L1 after being transfused into the body, thereby producing efficient specific cytotoxic effect on a tumor cell and improving the curative effect and reducing the side effect.
    Type: Application
    Filed: May 22, 2020
    Publication date: April 18, 2024
    Inventors: Chao Zhou, Hong An, Youde Lu, Ling Zhou, Yongbiao Du, Jiaqi Tu, Haibin Michael Yin
  • PROTECTED HDAC (HISTONE DEACETYLASE) INHIBITORS
    Publication number: 20240123072
    Abstract: The invention relates to protected HDAC inhibitor compounds of formula I, in which Y, Ar1, Ar2, X, R1 and R2 are as defined herein. In aspects, the inventions relates to use of the compounds, and to methods of deprotecting the compounds.
    Type: Application
    Filed: January 20, 2022
    Publication date: April 18, 2024
    Inventors: Andrew WHITING, David CHISHOLM, Alba PUJOL
  • NOVEL RIPK1 KINASE TARGETING PROTACS AND METHODS OF USE THEREOF
    Publication number: 20240123073
    Abstract: Novel small molecule proteolysis-targeting chimeras (PROTACs) are provided, along with methods for their use as RIPK1 kinase degraders. The small molecule PROTACs described herein are useful in treating and/or preventing RIPK1 kinase-related diseases, such as cancer, neurodegenerative disorders, and inflammatory diseases. Also provided are methods for promoting RIPK1 kinase degradation in a cell using the compounds and compositions described herein.
    Type: Application
    Filed: December 3, 2021
    Publication date: April 18, 2024
    Applicant: Baylor College of Medicine
    Inventors: Jin Wang, Dong Lu, Xin Yu
  • MINIMALLY TOXIC PRODRUGS
    Publication number: 20240123074
    Abstract: The present invention relates to the field of oligopeptide prodrugs that are intended for the treatment of cancer. The selectivity of these prodrugs requires the presence of an (oligo)peptidic moiety and/or a protective capping group to ensure the prodrug stability in blood. It further in particular relates to the exemplary oligopeptidic moiety ALGP and to prodrugs comprising it. In particular it also relates to the capping group phosphonoacetyl and to prodrugs comprising this capping group.
    Type: Application
    Filed: April 28, 2023
    Publication date: April 18, 2024
    Inventor: André TROUET
  • N-Oxide and Ectoine Monomers, Polymers, Their Compositions, and Related Methods
    Publication number: 20240123075
    Abstract: N-oxide and monomers, N-oxide polymers and copolymers, methods for making the N-oxide monomers, polymers, and copolymers, compositions and materials that include N-oxide polymers and copolymers, and methods for using the N-oxide monomers, N-oxide polymers, and N-oxide copolymers.
    Type: Application
    Filed: July 21, 2023
    Publication date: April 18, 2024
    Applicant: University of Washington
    Inventors: Shaoyi JIANG, Priyesh JAIN, Jinrong MA, Bowen Li
  • UNSATURATED DENDRIMERS COMPOSITIONS, RELATED FORMULATIONS, AND METHODS OF USE THEREOF
    Publication number: 20240123076
    Abstract: Described herein are novel lipid compositions comprising unsaturated dendrimers and methods of synthesis of unsaturated dendrimers. The lipid composition can comprise an ionizable cationic lipid, a phospholipid, and a selective organ targeting lipid. Also described herein are pharmaceutical formulations comprising an unsaturated dendrimer, a lipid composition, and a therapeutic agent. Further described in here are methods of mRNA delivery comprising a lipid composition and a therapeutic agent. Further described herein are high-potency dosage forms of a therapeutic formulated with a lipid composition.
    Type: Application
    Filed: December 9, 2021
    Publication date: April 18, 2024
    Applicant: The Board of Regents of The University of Texas System
    Inventors: Sang M. LEE, Daniel J. SIEGWART
  • PACLITAXEL-HYALURONIC ACID CONJUGATE IN THE TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCER
    Publication number: 20240123077
    Abstract: A pharmaceutical composition includes a paclitaxel prodrug associated with pharmacologically acceptable diluents/excipients for use in the treatment of non-muscle invasive bladder cancer (NMIBC) by intravesical instillations according to a single weekly dose of 600 mg of the prodrug, or two weekly doses equal to a total of 1,200 mg, for 12 or 6 consecutive weeks of treatment. The paclitaxel prodrug used was prepared according to an indirect synthesis process between molecules of hyaluronic acid (HA) and paclitaxel by introducing a spacer (4-bromobutyric acid) between the hyaluronic acid and chemotherapeutic agent.
    Type: Application
    Filed: December 14, 2023
    Publication date: April 18, 2024
    Applicant: FIDIA FARMACEUTICI S.P.A.
    Inventors: Giorgio MOSCONI, Daniela JABES, Carlo PIZZOCARO
  • COMPOUNDS AND METHODS FOR MODULATING IMMUNE-RELATED PROTEINS
    Publication number: 20240123078
    Abstract: Disclosed herein are methods, pharmaceutical compositions for modulating T cell proteins. Also disclosed herein are methods, pharmaceutical compositions, and vaccines for modulating an immune response.
    Type: Application
    Filed: October 15, 2020
    Publication date: April 18, 2024
    Inventors: Matthew PATRICELLI, Gabriel SIMON
  • IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES
    Publication number: 20240123079
    Abstract: The present disclosure provides, inter alia, antibody-drug conjugates that are useful in treating various diseases such as cancer.
    Type: Application
    Filed: July 14, 2023
    Publication date: April 18, 2024
    Inventors: Adam G. Hill, Elizabeth E. Gray, Elizabeth J. Cummins, Patrick J. Burke, Shyra J. Gardai
  • CYTOTOXIC COMPOUNDS AND CONJUGATES THEREOF
    Publication number: 20240123080
    Abstract: Hydrophilic auristatin compounds are described, including Drug-Linker compounds, Ligand-Drug Conjugate compounds, methods of use, and preparations thereof.
    Type: Application
    Filed: August 11, 2023
    Publication date: April 18, 2024
    Inventors: Philip MOQUIST, Svetlana DORONINA, Nicole DUNCAN, Gabriele BLAHNIK-FAGAN, Sharsti SANDALL
  • BRANCHED MOIETY FOR USE IN CONJUGATES
    Publication number: 20240123081
    Abstract: A tri-functional linker moiety: formula (I), where X and Y are linking chains, and its use for preparing dual-mechanistic drug conjugates, preferably in a site-specific manner.
    Type: Application
    Filed: October 25, 2019
    Publication date: April 18, 2024
    Inventors: Nazzareno DIMASI, Amit KUMAR
  • HYDROGEL PRODRUG FOR TREATMENT
    Publication number: 20240123082
    Abstract: Aspects of the invention described herein include a hydrogel prodrug and methods of making a hydrogel prodrug for drug delivery. Also contemplated are methods of treating, inhibiting, ameliorating or inhibiting a disease or disorder. Without being limiting, the methods for treatment can be directed to a cancer, HIV, a virus, pain, a bacterial infection, a neurological disorder, hemorrhaging, multiple sclerosis, diabetes, high blood pressure, Alzheimer's, or inhibiting a fungal growth in a subject in need.
    Type: Application
    Filed: June 1, 2023
    Publication date: April 18, 2024
    Inventors: Paul Fisher, Paulina Davis
  • HYBRID AAV-ANELLOVECTORS
    Publication number: 20240123083
    Abstract: This invention relates generally to compositions for making and administering anellovectors and uses thereof.
    Type: Application
    Filed: February 7, 2022
    Publication date: April 18, 2024
    Inventors: Simon Delagrave, Kevin James Lebo, Michael James DiBiasio-White, Dhananjay Maniklal Nawandar
  • LIVER SPECIFIC DELIVERY OF MESSENGER RNA
    Publication number: 20240123084
    Abstract: Disclosed herein are compositions and methods of modulating the expression of gene or the production of a protein by transfecting target cells with nucleic acids. The compositions disclosed herein demonstrate a high transfection efficacy and are capable of ameliorating diseases associated with protein or enzyme deficiencies.
    Type: Application
    Filed: June 13, 2023
    Publication date: April 18, 2024
    Inventors: Braydon Charles Guild, Frank DeRosa, Michael Heartlein